Published in JAMA on December 15, 2004
Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology (2009) 1.92
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol (2010) 1.78
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol (2007) 1.74
Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol (2009) 1.41
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat (2008) 1.40
Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol (2010) 1.33
Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr (2006) 1.32
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med (2013) 1.28
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis (2008) 1.26
Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol (2009) 1.22
Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction (2008) 1.20
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc (2011) 1.20
Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat (2007) 1.20
HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol (2014) 1.16
Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc (2011) 1.15
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis (2012) 1.14
The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat (2010) 1.11
Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients. BMC Infect Dis (2014) 1.11
Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS (2009) 1.10
Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol (2011) 1.10
Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res (2006) 1.09
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis (2012) 1.08
Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J Interferon Cytokine Res (2010) 1.07
Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection. Sex Transm Infect (2006) 1.06
Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk. AIDS Patient Care STDS (2011) 1.05
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther (2008) 1.02
Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol (2016) 1.02
Complete genome of a European hepatitis C virus subtype 1g isolate: phylogenetic and genetic analyses. Virol J (2008) 0.99
Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2011) 0.99
Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther (2008) 0.99
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr (2010) 0.97
Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment. AIDS Patient Care STDS (2011) 0.95
Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr (2009) 0.94
Chronic hepatitis C. Gut Liver (2011) 0.94
Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline. Curr HIV/AIDS Rep (2012) 0.94
Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis (2012) 0.93
Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci (2011) 0.92
Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis (2008) 0.92
HCV-HIV coinfection: simple messages from a complex disease. PLoS Med (2007) 0.91
Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol (2010) 0.91
Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep (2006) 0.91
Hepatitis C treatment experiences and decision making among patients living with HIV infection. J Assoc Nurses AIDS Care (2009) 0.90
Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India. J Clin Exp Hepatol (2014) 0.90
Hepatitis e virus infection in sheltered homeless persons, france. Emerg Infect Dis (2012) 0.89
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis (2010) 0.89
Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med (2013) 0.89
The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther (2010) 0.89
Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol (2007) 0.88
Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. J Viral Hepat (2011) 0.88
Co-infection by hepatitis C virus in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates. PLoS One (2010) 0.88
Therapeutic challenges in hepatitis C-infected injection drug using patients. Harm Reduct J (2006) 0.88
Epidemiological features of patients infected with HCV genotype 4 in Poland: Epidemiology of HCV genotype 4 in Poland. Hepat Mon (2011) 0.88
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. J Acquir Immune Defic Syndr (2010) 0.87
Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis (2010) 0.87
Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment. AIDS Patient Care STDS (2009) 0.87
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS (2014) 0.87
Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials (2012) 0.86
Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline. J Infect Dis (2012) 0.86
Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults. AIDS Care (2012) 0.85
Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse. Subst Abus (2008) 0.85
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol (2013) 0.84
Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Antimicrob Agents Chemother (2012) 0.84
Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol (2006) 0.84
Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug Alcohol Depend (2010) 0.84
In the clinic. Hepatitis C. Ann Intern Med (2008) 0.84
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother (2010) 0.84
Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. Curr HIV/AIDS Rep (2013) 0.83
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. AIDS Res Hum Retroviruses (2013) 0.83
Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis (2008) 0.83
Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol (2010) 0.82
Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy. J Acquir Immune Defic Syndr (2012) 0.82
Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step. JAMA (2004) 0.82
Recent advances in management of the HIV/HCV coinfected patient. Future Virol (2016) 0.81
Update on Hepatitis B and C Coinfection in HIV. Curr Infect Dis Rep (2005) 0.81
Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study. Dig Dis Sci (2007) 0.81
Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil. PLoS One (2013) 0.80
Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients. AIDS Res Treat (2011) 0.80
Management of Hepatitis C in HIV-infected Patients. Curr Infect Dis Rep (2005) 0.80
Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients. AIDS Behav (2013) 0.80
Latest approved therapies for metastatic melanoma: what comes next? J Skin Cancer (2013) 0.80
Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. PLoS One (2012) 0.79
Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices. Gen Hosp Psychiatry (2009) 0.79
The treatment of chronic hepatitis C virus infection in HIV co-infection. Eur J Med Res (2009) 0.79
Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr (2008) 0.79
Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision. Ther Clin Risk Manag (2010) 0.79
Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients. Ther Clin Risk Manag (2008) 0.79
Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat (2010) 0.79
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals. Eur J Med Res (2010) 0.79
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med (2002) 7.52
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet (2006) 5.72
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology (2007) 5.53
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med (2015) 5.30
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol (2009) 4.38
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med (2008) 3.54
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (2008) 3.44
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis (2009) 3.28
Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS (2007) 3.25
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis (2013) 2.99
Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med (2002) 2.98
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis (2010) 2.90
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum (2010) 2.68
Leiomyosarcoma of the inferior vena cava: experience in 22 cases. Ann Surg (2006) 2.65
CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood (2011) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest (2010) 2.43
A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med (2014) 2.39
Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol (2002) 2.30
Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) (2004) 2.27
Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol (2009) 2.24
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 2.22
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS (2002) 2.21
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology (2011) 2.16
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14
Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr (2004) 2.12
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum (2006) 2.09
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy. Ann Intern Med (2002) 2.05
Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke (2005) 2.03
Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol (2012) 2.03
Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients. Ultrasound Med Biol (2011) 2.02
Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis (2011) 2.01
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 2.00
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
Brugada phenocopy with a flecainide overdose: a pharmacological dose effect? J Cardiovasc Electrophysiol (2013) 1.98
Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol (2009) 1.98
Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum (2007) 1.97
Behçet's disease and pregnancy. Arthritis Rheum (2013) 1.96
Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med (2002) 1.94
Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood (2008) 1.94
Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol (2011) 1.94
CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol (2004) 1.93
Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol (2005) 1.90
Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J Exp Med (2005) 1.85
Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol (2006) 1.83
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS (2006) 1.76
Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS (2009) 1.74
Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood (2012) 1.73
Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) (2014) 1.65
Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int (2011) 1.64
Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis (2005) 1.64
Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood (2010) 1.64
Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum (2009) 1.64
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS (2006) 1.61
Viral hepatitis in solid organ transplantation other than liver. J Hepatol (2011) 1.61
Performance of a predictive rule to distinguish bacterial and viral meningitis. J Infect (2006) 1.61
CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis (2013) 1.60
New insights into the pathogenesis of Behçet's disease. Autoimmun Rev (2011) 1.60
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet (2005) 1.58
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis (2002) 1.57
Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem (2007) 1.57
Endocardial pacemaker implantation in infants weighing < or = 10 kilograms. Pacing Clin Electrophysiol (2004) 1.56
Histologic scoring of liver biopsy in focal nodular hyperplasia with atypical presentation. Hepatology (2002) 1.55
Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother (2002) 1.55
Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum (2009) 1.55
Acquired hemophilia in older people: a poor prognosis despite intensive care. J Am Geriatr Soc (2007) 1.54
Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis (2005) 1.54
Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology (2005) 1.54
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One (2012) 1.53
The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS (2004) 1.52
Splenic infarction during acute malaria. Trans R Soc Trop Med Hyg (2005) 1.51
Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol (2010) 1.51
Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol (2006) 1.49